This document discusses floating tablet technology as a novel oral drug delivery system for controlled release. Floating tablets are gastroretentive drug delivery systems that float on the gastric contents and remain in the stomach for an extended period of time, allowing for sustained drug release at the absorption site. Some key advantages of floating tablets include improved bioavailability, increased duration of drug release, and minimized drug degradation in the colon. The document reviews different types of floating systems and polymers used in their formulation. It also discusses evaluation tests and provides examples of research on developing floating tablets with silymarin as a model drug.

1. Flouting tablet as a novel technology of
oral drug delivery system
Laith J. Al-Asadi

2. Introduction
• Oral administration is the most convenient and preferred
means of any drug delivery to the systematic circulation.
• Oral controlled release drug delivery have recently been of
increasing interest in pharmaceutical field to achieve
improved therapeutic advantages, such as :
 ease of administration.
 patient compliance.
 flexibility in formulation.

3. Controlled release systems
• Drugs that are easily absorbed from
gastrointestinal tract (GIT) and have short
half-lives are eliminated quickly from the
systemic circulation.
• Frequent dosing of these drugs is required to
achieve suitable therapeutic activity.
• To avoid this limitation, the development of
oral sustained-controlled release
formulations.

4. Controlled release systems
• After oral administration, such a drug delivery would
be retained in the stomach and release the drug in a
controlled manner.
• So that the drug could be supplied continuously to its
absorption sites in the gastrointestinal tract (GIT).
• To formulate a site-specific orally administered
controlled release dosage form, it is desirable to
achieve a prolong gastric residence time by the drug
delivery.

5. Gastro-retentive drug delivery system
• Gastro-retentive drug delivery is an approach to
prolong gastric residence time, there by targeting
site-specific drug release and localized in the
stomach and upper gastrointestinal tract for local or
systemic effects.
• GRDS have a bulk density less than gastric fluids, so
remain buoyant in the stomach without affecting
the gastric emptying rate for a prolonged period of
time.

6. Advantages :
• Improve bioavailability.
• Increases the duration of drug release.
• Reduces drug waste.
• Improves the drug solubility that are less soluble
in a high pH environment.
• Provide local action in the upper part of the
small intestine e.g. treatment of peptic ulcer,
etc.
• Minimized adverse activity at the colon.

7. Drugs candidate to formulated as
GRDDS
• Drugs that absorbed from stomach
(levodopa and furosemide).
• Drugs with variable bioavailability (sotalol).
• Drugs acting locally in the stomach
(misoprostol).
• Poorly soluble drugs at alkaline PH
(diazepam ).
• Drugs that degraded in colon (ranitidine ,
metronidazole).

8. Drugs not intended to formulate as
grdds
• Drugs that have limited acid solubility.
(phenytoin).
• Drugs that instable in gastric condition.
(erythromycin).
• Drugs that cause gastric lesions(NSAIDs).
• Drugs have wide absorption sites
(nifedipine).

9. Gastro-retentive systems
• high density (sinking) systems.
• low density (floating) systems.
• mucoadhesive systems.
• swellable systems.
• super porous hydrogel systems.

11. Floating drug delivery system
• Floating drug delivery is the system float on the
gastric contents.
• FDDS have a bulk density less than gastric fluid.
• The drug is released slowly at the desired rate
from the system.
• After release of the drug, the residual system is
emptied from the stomach.
• This results in an increased GRT and a better
control of the fluctuations in plasma drug
concentration.

12. Limitation Of FDDS:
• These systems require a high level of fluid in
the stomach.
• Patients should not be dosed with floating
forms just before going to bed.
• Not suitable for drugs that have solubility or
stability problem in GIT.

13. Limitation Of FDDS:
• Drugs which are irritant to gastric mucosa are
also not desirable or suitable.
• The drug substances that are unstable in the
acidic environment of the stomach.
• These systems do not offer significant advantages
over the conventional dosage. forms for drugs
which are absorbed throughout the
gastrointestinal tract.

14. CLASSIFICATION OF FLOATING DRUG
DELIVERY SYSTEM
Single Unit Floating Dosage Systems .
Multiple Unit Floating Dosage Systems.
 Non-effervescent Systems.
 Effervescent Systems (Gas-generating systems).
 Hollow Microspheres.
 Raft Forming Systems.

16. Polymers used in formulation of FDDS
 Guar gum
 Chitosan
 Xanthum gum
 Gellan gum
 Sodium alginate

17. EVALUATION TESTS
• Hardness & thickness
• Weight variation
• Content uniformity
• Powder compressibility & followability
• Friability
• Flouting time
• Density
• In-vitro release

18. Development and evaluation of flouting tablet
for gastric retention using silymarin as a model
drug by Vundeti Srilekha 2018

19. Dissolution data of sylimarin flouting tablet

20. References :
 Samadhan Mali, S.Talele, A.Jadhav “ Effervescent Floating
Drug Delivery System: A Review” , Human Journals
Review Article March 2020 Vol.:17, Issue:4
 Shaika Saadia Zubedi, Shahid “Flouting tablets and its
polymers” , Mohammed Journal of Drug Delivery &
Therapeutics. , 2018; 8(5-s):16-24
 Vundeti Srilekha and Dr. M. Dhanalakshmi “Development
and evaluation of flouting tablet for gastric retention
using silymarin as a model drug” , wjpmr, 2018,4(12),
242-253

21. References :
 Harshal Ashok Pawar, Pooja Ramchandra Gharat
et al. “Development and evaluation of gastro-
retentive flouting tablet of antihypertensive drug
using hydrogenated cottonseed oil” , ISRN
Pharm. 2013; 2013: 137238.
 Dr. Sameer Shakur Sheaikh “Current technologies
for enhancing oral drug delivery system” ,
International Journal of Research in Pharmacy and
Biosciences / Volume 4, Issue 10, 2017, PP 1-10